Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887609 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
A Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 5
- Study locations
NCT05887609 is a Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 53 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05887609, a Phase 2 study of Fallopian Tube Cancer and Peritoneal Cancer, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Mirvetuximab Soravtansine-gynx
Study Locations (5)
Pennsylvania
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine - Philadelphia
- UPMC Magee-Women's Hospital - Pittsburgh
Colorado
- University of Colorado Hospital - Aurora
Illinois
- Northwestern Memorial Hospital - Chicago
Wisconsin
- University of Wisconsin - Carbone Cancer Center - University Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05887609
The ClinicalTrials.gov registry entry for NCT05887609 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (79% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT05887609 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Pennsylvania, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT05887609 about?
NCT05887609 is a clinical study titled "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib". The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
What is the current status of trial NCT05887609?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2023-10-03. Estimated completion is 2028-10.
What conditions does trial NCT05887609 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Peritoneal Cancer, Ovary Cancer.
What interventions are being tested in trial NCT05887609?
The interventions under investigation include: Olaparib (DRUG), Mirvetuximab Soravtansine-gynx (DRUG).
Who is sponsoring clinical trial NCT05887609?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887609 being conducted?
This trial has 5 study locations across Colorado, Illinois, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.